Angiogenic inhibitors and radiotherapy: From the concept to the clinical trial;Thérapies antiangiogéniques et radiothérapie : du concept à l'essai clinique

Cancer/Radiotherapie

Volumn 13, Issue 6-7, 2009, Pages 562-567

  Cohen Jonathan Moyal, E ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Angiogenesis; Clinical trial; FGF 2; HIF 1; Hypoxia; Integrins; Radiotherapy; Stem cells; VEGF

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 2 NITROIMIDAZOLE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CILENGITIDE; COMBRETASTATIN; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; MISONIDAZOLE; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TIPIFARNIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VITRONECTIN RECEPTOR; HIF1A PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HYPOXIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RADIOSENSITIVITY; SHORT SURVEY; BIOSYNTHESIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIOTHERAPY; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RADIOTHERAPY;

EID: 70350736322     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2009.07.007     Document Type: Short Survey

References (71)

1. Abdollahi A., Griggs D.W., Zieher H., Roth A., Lipson K.E., Saffrich R., et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11 (2005) 6270-6279
2. Ader I., Delmas C., Bonnet J., Rochaix P., Favre G., Toulas C., et al. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 22 (2003) 8861-8869
3. Ader I., Muller C., Bonnet J., Favre G., Cohen-Jonathan E., Salles B., et al. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene 21 (2002) 6471-6479
4. Ader I., Toulas C., Dalenc F., Delmas C., Bonnet J., Cohen-Jonathan E., et al. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21 (2002) 5998-6006
5. Albert J.M., Cao C., Geng L., Leavitt L., Hallahan D.E., and Lu B. Integrin alpha(v)beta3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65 (2006) 1536-1543
6. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11 (2005) 743-750
7. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
8. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
9. Bernsen H.J., Rijken P.F., Peters J.P., Bakker J.H., Boerman R.H., Wesseling P., et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neuro Oncol 44 (1999) 129-136
10. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
11. Bredel M., Pollack I.F., Campbell J.W., and Hamilton R.L. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res 3 (1997) 2157-2164
12. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
13. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
14. Cohen-Jonathan E., Muschel R.J., Gillies M.W., Evans S.M., Cerniglia G., Mick R., et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154 (2000) 125-132
15. Cohen-Jonathan E., Toulas C., Monteil S., Couderc B., Maret A., Bard J.J., et al. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 57 (1997) 1364-1370
16. Cohen-Jonathan M.E., Laprie A., Delannes M., Poublanc M., Catalaa I., Dalenc F., et al. Phase I Trial of Tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2007)
17. Crane C.H., Ellis L.M., Abbruzzese J.L., Amos C., Xiong H.Q., Ho L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
18. Czito B.G., Bendell J.C., Willett C.G., Morse M.A., Blobe G.C., Tyler D.S., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68 (2007) 472-478
19. de Cremoux P., Gauville C., Closson V., Linares G., Calvo F., Tavitian A., et al. EGF modulation of the ras-related RhoB gene expression in human breast-cancer cell lines. Int J Cancer 59 (1994) 408-415
20. Delmas C., End D., Rochaix P., Favre G., Toulas C., and Cohen-Jonathan E. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 9 (2003) 6062-6068
21. Delmas C., Heliez C., Cohen-Jonathan E., End D., Bonnet J., Favre G., et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100 (2002) 43-48
22. Fenton B.M., Paoni S.F., and Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 72 (2004) 221-230
23. Folkins C., Man S., Xu P., Shaked Y., Hicklin D.J., and Kerbel R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67 (2007) 3560-3564
24. Fritz G., and Kaina B. RhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase. J Biol Chem 272 (1997) 30637-30644
25. Fukui S., Nawashiro H., Otani N., Ooigawa H., Nomura N., Yano A., et al. Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. Cancer 97 (2003) 3061-3067
26. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
27. Gloe T., Sohn H.Y., Meininger G.A., and Pohl U. Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin alpha(v)beta3. J Biol Chem 277 (2002) 23453-23458
28. Gonzalez J., Kumar A.J., Conrad C.A., and Levin V.A. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67 (2007) 323-326
29. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
30. Gruber G., Hess J., Stiefel C., Aebersold D.M., Zimmer Y., Greiner R.H., et al. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer 92 (2005) 41-46
31. Haimovitz-Friedman A., Balaban N., McLoughlin M., Ehleiter D., Michaeli J., Vlodavsky I., et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54 (1994) 2591-2597
32. Haimovitz-Friedman A., Vlodavsky I., Chaudhuri A., Witte L., and Fuks Z. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51 (1991) 2552-2558
33. Harari P.M., and Huang S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49 (2001) 427-433
34. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001) 2010-2016
35. 2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 345 (1994) 445-450
36. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
37. Horsman M.R., and Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66 (2006) 11520-11539
38. Kadambi A., Mouta C.C., Yun C.O., Padera T.P., Dolmans D.E., Carmeliet P., et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 61 (2001) 2404-2408
39. Kermani P., Leclerc G., Martel R., and Fareh J. Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys 50 (2001) 213-220
40. Kim W.Y., Oh S.H., Woo J.K., Hong W.K., and Lee H.Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 69 (2009) 1624-1632
41. Koch C.J., and Evans S.M. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 510 (2003) 285-292
42. Lai A., Filka E., McGibbon B., Nghiemphu P.L., Graham C., Yong W.H., et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71 (2008) 1372-1380
43. Laprie A., Catalaa I., Cassol E., McKnight T.R., Berchery D., Marre D., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 70 (2008) 773-781
44. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9 (2006) 391-403
45. Massabeau C., Rouquette I., Lauwers-Cances V., Mazieres J., Bachaud J.M., Armand J.P., et al. Basic fibroblast growth factor-2/beta3 integrin expression profile: Signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2009)
46. Milia J., Teyssier F., Dalenc F., Ader I., Delmas C., Pradines A., et al. Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ 12 (2005) 492-501
47. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
48. Monferran S., Skuli N., Delmas C., Favre G., Bonnet J., Cohen-Jonathan-Moyal E., et al. Alpha(v)beta3 and alpha(v)beta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer 123 (2008) 357-364
49. Murata R., Nishimura Y., and Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37 (1997) 1107-1113
50. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5.6-dimethylxanthenone-4-acetic acid. Radiat Res 156 (2001) 503-509
51. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60 (2001) 155-161
52. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
53. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15 (2009) 392-400
54. Riesterer O., Honer M., Jochum W., Oehler C., Ametamey S., and Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12 (2006) 3518-3524
55. Rischin D., Hicks R.J., Fisher R., Binns D., Corry J., Porceddu S., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
56. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., Todd D.G., Valerie K., Kavanagh B.D., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
57. Segers J., Fazio V.D., Ansiaux R., Martinive P., Feron O., Wallemacq P., et al. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the "normalization" window of the tumor vasculature. Cancer Lett 244 (2006) 129-135
58. Senan S., and Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12 (2007) 465-477
59. Skuli N., Monferran S., Delmas C., Favre G., Bonnet J., Toulas C., et al. Alpha(v)beta3/alpha(v)beta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69 (2009) 3308-3316
60. Skuli N., Monferran S., Delmas C., Lajoie-Mazenc I., Favre G., Toulas C., et al. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res 66 (2006) 482-489
61. Sonveaux P., Brouet A., Havaux X., Gregoire V., Dessy C., Balligand J.L., et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63 (2003) 1012-1019
62. Stupp R, Goldbrunner R, Neyns B, Schlegel U, Clement P, Grabenbauer G et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 25. 20-6-2007. Ref Type: Abstract.
63. Thorwarth D., Eschmann S.M., Paulsen F., and Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 68 (2007) 291-300
64. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
65. Wachsberger P.R., Burd R., Marero N., Daskalakis C., Ryan A., McCue P., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
66. Weppler S.A., Krause M., Zyromska A., Lambin P., Baumann M., and Wouters B.G. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82 (2007) 96-104
67. Wild-Bode C., Weller M., Rimner A., Dichgans J., and Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61 (2001) 2744-2750
68. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
69. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Czito B.G., Vujaskovic Z., et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 4 (2007) 316-321
70. Williams K.J., Telfer B.A., Brave S., Kendrew J., Whittaker L., Stratford I.J., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
71. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563